Manila Times Business
Elixiron Immunotherapeutics Reports Positive Phase 2 Interim Results for Enrupatinib: Evidence of Neuroinflammation Reduction and Early Cognitive Benefit in Alzheimer's Disease
CAMBRIDGE, Mass. and TAIPEI, June 11, 2026 /PRNewswire/ -- Elixiron Immunotherapeutics (TPEx: 7871), a clinical-stage biopharmaceutical company pioneering precision immunotherapy for neurodegenerative and autoimmune diseases, today announced positive interim results from its ongoing Phase 2 proof-of-concept study of enrupatinib (EI-1071), a brain-penetrant colony-stimulating factor 1 receptor (CSF-1R) inhibitor designed to modulate neuroinflammation in Alzheimer's disease (AD). The study is supp
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
Volcano Engine and Bingo Group Launch In-depth AI+IP Partnership, AI Features Roll Out Across Multiple Chinese Platforms on June 10
2h ago
GWM TANK 700 Hi4-T Wins 11 of 13 Stages at 2026 Taklimakan Rally
2h ago
Watch : Public Works chief leads clean-up of Wetland Park
2h ago
Rene Baterbonia's remains to be flown to Agusan del Sur on Independence Day
2h ago